Details

Autor(en) / Beteiligte

• Lunzen, Jan van
• Glaunsinger, Tobias
• Stahmer, Ingrid
• Baehr, Volker von
• Baum, Christopher
• Schilz, Andrea
• Kuehlcke, Klaus
• Naundorf, Sonja
• Martinius, Holger
• Hermann, Felix
• Giroglou, Tsanan
• Newrzela, Sebastian
• Müller, Ingrid
• Brauer, Francis
• Brandenburg, Gunda
• Alexandrov, Alexander
• von Laer, Dorothee

Titel

Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus

Ist Teil von

• Molecular therapy, 2007-05, Vol.15 (5), p.1024

Ort / Verlag

United States

Erscheinungsjahr

2007

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Drug toxicity and viral resistance limit the long-term efficacy of antiviral drug treatment for human immunodeficiency virus (HIV) infection. Thus, alternative therapies need to be explored. We tested the infusion of T lymphocytes transduced with a retroviral vector (M87o) that expresses an HIV entry-inhibitory peptide (maC46). Gene-modified autologous T cells were infused into ten HIV-infected patients with advanced disease and multidrug-resistant virus during anti-retroviral combination therapy. T-cell infusions were tolerated well, with no severe side effects. A significant increase of CD4 counts was observed after infusion. At the end of the 1-year follow-up, the CD4 counts of all patients were still around or above baseline. Gene-modified cells could be detected in peripheral blood, lymph nodes, and bone marrow throughout the 1-year follow-up, and marking levels correlated with the cell dose. No significant changes of viral load were observed during the first 4 months. Four of the seven patients who changed their antiviral drug regimen thereafter responded with a significant decline in plasma viral load. In conclusion, the transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus.